Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
Web: cytokines.ru


Year 2016
Number 1 Number 2
Number 3 Number 4

About journal

Current year


Rules for authors

Contact us


Site map

Our partners:


Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2016, No. 3

Subscribe for 2018 year

Order this issue

Order PDF of this article

Original Articles

Number 3'2016

Effects of a short and prolonged course of local cytokine therapy with interleukin 2 in a spontaneous mouse breast cancer model

S.G. Semushina, D.A. Aronov, E.V. Moiseeva

We developed novel approaches to evaluate interleukin 2 (IL-2) efficacy in the spontaneous (naturally arising) BLRB/BYRB mouse model of breast cancer (BC). We used the principle “each mouse is a patient” and demonstrated that efficacy of local IL-2 application depends on tumor growth parameters and recipient characteristics as well as the disease stage when IL-2 was applied. The aim of this research was to compare the efficacy of the short and the prolonged course of the local IL-2 therapy in the BLRB/BYRB model, standardized according to the age and the initial tumor diameter. Materials and methods. Female mice at the age of 15 months with tumor diameter of 4–6 mm were divided into groups: (i) short course of a single peritumoral IL-2 application, (ii) prolonged course of three peri- and intratumoral IL-2 applications, and (iii) the control untreated group. The tumor growth rate and recipient survival were estimated individually after the start of the cytokine therapy. Results. The tumor growth rate was decreased in both experimental groups when compared to untreated control. Single IL-2 application resulted in a significant increase in the average survival while the prolonged course caused tumor rejection in two females and a decrease in the survival of the rest of recipients. Conclusion. In order to choose the most successful regimen of the IL-2 therapy in the spontaneous BC model, it is necessary to decide whether it is more important to improve the average survival of the group (short course) or to cure a few individual patients completely risking to decrease the survival of the rest (prolonged course). (Cytokines and Inflammation. 2016. Vol. 15. № 3–4. P. 275–279.)

Keywords: breast cancer, interleukin-2, immunotherapy, spontaneous mouse model.

Contents | Next article | Previous article

© 2007-2017 Cytokines and inflammation